Abstract
Background:
Cisplatin is a commonly used chemotherapy agent for solid tumors, including lung, ovarian, testicular, bladder, and oral cancers. However, it can cause significant adverse drug reactions (ADRs).

Aim: Therefore, this study aimed to evaluate the experience of patients with cancer undergoing chemotherapy by estimating the number of ADRs
associated with cisplatin treatment.

Methods:
Prospective observational research was conducted in a hospital setting by the Department of Pharmacology in collaboration with the Department of Oncology in Shree Krishna Hospital, Karamsad, Anand, Gujarat, from February 18, 2023, to February 29, 2024. The study included 105 patients at the daycare center who were receiving cisplatin-based chemotherapy for the first time for solid cancer tumors. Sample size calculation was done based on the number of patients admitted to daycare for cisplatin treatment.

Results:
Of the 105 participants, most (70.48%) were male, with a mean age of 49.03 years; the majority of them were receiving treatment for malignancies of the buccal mucosa and oral cavity. Cisplatin was administered according to the protocol, with antiemetic and hydration measures to mitigate adverse effects. Nephrotoxicity, tinnitus, vomiting, hearing loss, and loss of taste were notable ADRs among the study participants.

Conclusion:
ADRs, such as vomiting, nephrotoxicity, tinnitus, and loss of taste, were noted at different frequencies during each cycle. Most of the studies were mild but not preventable, and they had no impact on the patients’ course of therapy.